George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.44
Bid: 41.60
Ask: 41.70
Change: 0.56 (1.37%)
Spread: 0.10 (0.24%)
Open: 41.36
High: 41.70
Low: 40.84
Prev. Close: 40.88
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

13 Jan 2020 07:00

RNS Number : 5048Z
Assura PLC
13 January 2020
 

13 January 2020

Assura plc

 

Trading Update

For the third quarter ending 31 December 2019

 

Continued strong performance

 

Assura plc ("Assura"), the leading primary care property investor and developer, today announces its Trading Update for the third quarter ending 31 December 2019.

 

Jonathan Murphy, CEO, said:

 

"Assura continued to make strong progress in the third quarter. We expanded our market-leading portfolio with the acquisition of six high-quality assets and completed our third development of the year in Stow-on-the-Wold. We also grew our immediate pipeline of acquisition and development opportunities, reinforcing what was already our strongest in 10 years, to £252 million including 13 developments currently on site."

 

"With the new Government enshrining in law increased funding for the NHS and taking forward the Health Infrastructure Plan, better primary care facilities for patients, staff and services are at the heart of the agenda. In this context, Assura is well positioned to deliver high-quality assets and value for money for the NHS."

 

Building the portfolio

·; Current portfolio of 563 properties.

·; Development completed at Stow-on-the-Wold, taking total to three completed year to date at a total cost of £11.8 million.

·; Currently on site with 13 developments at the period end with a total development cost of £66 million.

·; Six acquisitions completed in the period at a cost of £31.1 million; four disposals made for cash proceeds of £1.0 million.

 

Expanding the pipeline

·; Immediate development pipeline further increased to £90 million, up from £72 million at September 2019.

·; Immediate acquisitions pipeline further increased to £96 million, up from £65 million at September 2019.

·; Total immediate pipeline, including on site developments, worth £252 million, up from £206 million at September 2019.

 

Growing the rent roll

·; Five lease re-gears completed in the quarter taking cumulative year-to-date re-gears to 18. These leases represent £1.7 million of the Group's rent roll, adding a weighted average of 10.2 years WAULT to those 18 leases.

·; Annualised rent roll at £105.8 million taking account of additions, disposals and rent reviews.

 

Robust balance sheet

·; As at 31 December 2019 gross debt stood at £787 million with undrawn facilities of £280 million.

 

As previously announced, the quarterly dividend has been increased to 0.697 pence per share with effect from January 2020. This is equivalent to 2.788 pence per share on an annualised basis.

 

ENDS

 

 

For further information, please contact:

 

Assura plc:

Jayne Cottam, CFO

David Purcell, Head of Financial Reporting

 

Tel: 01925 420 660

 

Finsbury:

Gordon Simpson

James Thompson

 

Tel: 0207 251 3801

 

This announcement contains inside information as defined in Article 7 of the EU Market Abuse Regulation No 596/2014 and has been announced in accordance with the Company's obligations under Article 17 of that Regulation.

 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2019, Assura's property portfolio was valued at £2,039 million.

 

Further information is available at www.assuraplc.com

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFERLEIILII
Date   Source Headline
14th Jun 20239:01 amRNSHolding(s) in Company
12th Jun 20234:23 pmRNSDirector/PDMR Shareholding
5th Jun 202310:54 amRNSDirector/PDMR Shareholding
2nd Jun 20237:00 amRNSAnnual Report & Notice of AGM
1st Jun 20237:00 amRNSNotice of Dividend
23rd May 20237:00 amRNSAssura Full Year Results 2023
12th May 20237:00 amRNSNotice of Results
10th May 202310:53 amRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSTotal Voting Rights
25th Apr 20234:12 pmRNSHolding(s) in Company
17th Apr 20234:06 pmRNSDirector/PDMR Shareholding
11th Apr 20238:43 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSScrip Dividend Declaration
16th Mar 202310:13 amRNSScrip Calculation Price
13th Mar 20237:00 amRNSMSCI ESG rating upgrade and energy reduction pilot
7th Mar 202310:43 amRNSDirector/PDMR Shareholding
2nd Mar 20237:00 amRNSNotice of Dividend
15th Feb 20231:51 pmRNSHolding(s) in Company
7th Feb 20239:57 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSTotal Voting Rights
26th Jan 20231:48 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSTrading Update
13th Jan 20232:55 pmRNSDirector/PDMR Shareholding
9th Jan 202311:33 amRNSDirector/PDMR Shareholding
9th Jan 20237:00 amRNSScrip Dividend Declaration
15th Dec 20229:07 amRNSScrip calculation price
6th Dec 20229:03 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSDividend Declaration
22nd Nov 20227:00 amRNSDelivering continued growth
15th Nov 202212:15 pmRNSHolding(s) in Company
8th Nov 20229:02 amRNSDirector/PDMR Shareholding
1st Nov 20222:02 pmRNSHolding(s) in Company
31st Oct 20228:43 amRNSTotal Voting Rights
17th Oct 202212:10 pmRNSDirector/PDMR Shareholding
11th Oct 20221:49 pmRNSHolding(s) in Company
10th Oct 20227:00 amRNSScrip Dividend Declaration
7th Oct 202210:14 amRNSDirector/PDMR Shareholding
5th Oct 20227:00 amRNSTrading Update
15th Sep 20227:00 amRNSScrip calculation price
14th Sep 20225:37 pmRNSDirector/PDMR Shareholding
13th Sep 20224:28 pmRNSHolding(s) in Company
1st Sep 20227:00 amRNSDividend Declaration
8th Aug 202212:51 pmRNSDirector/PDMR Shareholding
29th Jul 20229:27 amRNSTotal Voting Rights
18th Jul 20222:53 pmRNSDirector/PDMR Shareholding
13th Jul 20225:17 pmRNSExercise of Nil Cost Options under PSP
13th Jul 20227:00 amRNSDirector/PDMR Shareholding
12th Jul 20227:00 amRNSAdditional Listing
11th Jul 20227:00 amRNSScrip Dividend Declaration
7th Jul 20228:07 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.